Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
